Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Methionine De Novo and Salvage Pathway WP3580,0.003462964314687189,7.596536796536797,43.03916918895387,"['AHCY', 'CHDH', 'ODC1', 'MTR']",0.9163594538883383,0,0,4
2,NRF2 pathway WP2884,0.013286015381529584,2.7223955084217093,11.763588795429799,"['CBR1', 'SLC6A9', 'FTH1', 'TXNRD1', 'GSR', 'SLC39A11', 'SLC5A3', 'PRDX6']",0.9163594538883383,0,0,8
3,Ketogenesis and Ketolysis WP4742,0.021817555581619706,11.354310344827587,43.43069500373834,"['CPT2', 'OXCT1']",0.9163594538883383,0,0,2
4,Sleep regulation WP3591,0.02930835106581287,5.0154999364756705,17.704126880214485,"['AHCY', 'ADORA1', 'PTGDS']",0.9163594538883383,0,0,3
5,Folate-Alcohol and Cancer Pathway Hypotheses WP1589,0.03575064374689539,8.108990147783251,27.01256258854593,"['ALDH1A1', 'MTR']",0.9163594538883383,0,0,2
6,Methionine metabolism leading to sulfur amino acids and related disorders WP4292,0.03575064374689539,8.108990147783251,27.01256258854593,"['AHCY', 'MTR']",0.9163594538883383,0,0,2
7,Prostaglandin Synthesis and Regulation WP98,0.0422464465956785,4.262203023758099,13.486612125364315,"['CBR1', 'TBXAS1', 'PTGDS']",0.9163594538883383,0,0,3
8,Trans-sulfuration pathway WP2333,0.04369535188320607,7.094827586206897,22.21045387059238,"['AHCY', 'MTR']",0.9163594538883383,0,0,2
9,Eicosanoid Synthesis WP167,0.04369535188320607,7.094827586206897,22.21045387059238,"['TBXAS1', 'PTGDS']",0.9163594538883383,0,0,2
10,Iron metabolism in placenta WP2007,0.04369535188320607,7.094827586206897,22.21045387059238,"['FTH1', 'ACO1']",0.9163594538883383,0,0,2
11,White fat cell differentiation WP4149,0.04709624924080371,4.058932428262882,12.40231934369919,"['CTNNA1', 'RORA', 'KLF2']",0.9163594538883383,0,0,3
12,Ethanol effects on histone modifications WP3996,0.05220706516195099,3.8741409778126843,11.43854630544893,"['AHCY', 'ALDH1A1', 'MTR']",0.9163594538883383,0,0,3
13,Dopaminergic Neurogenesis WP2855,0.052222343347787546,6.306034482758621,18.616957776404135,"['ALDH1A1', 'GLI1']",0.9163594538883383,0,0,2
14,GPR40 Pathway WP3958,0.052222343347787546,6.306034482758621,18.616957776404135,"['PLCE1', 'PLCD1']",0.9163594538883383,0,0,2
15,miR-509-3p alteration of YAP1/ECM axis WP3967,0.052222343347787546,6.306034482758621,18.616957776404135,"['COL5A1', 'TEAD1']",0.9163594538883383,0,0,2
16,One-carbon metabolism WP241,0.057573413905223934,3.705418349140764,10.577836944174885,"['AHCY', 'CHDH', 'MTR']",0.9163594538883383,0,0,3
17,Phosphoinositides metabolism WP4971,0.06674751727127522,2.7737303347059443,7.508039162217202,"['MTMR10', 'INPP5D', 'PLCE1', 'PLCD1']",0.9163594538883383,0,0,4
18,Cysteine and methionine catabolism WP4504,0.08082145961419902,4.728448275862069,11.894471970250178,"['AHCY', 'MTR']",0.9163594538883383,0,0,2
19,Alzheimer's disease WP2059,0.08245577603763904,2.257514719553765,5.633612580515723,"['BACE1', 'PPP3CB', 'CAPN2', 'ADAM10', 'MAPT']",0.9163594538883383,0,0,5
20,Nuclear Receptors Meta-Pathway WP2882,0.08409128709362271,1.652353961827646,4.090984388382863,"['NCOA1', 'CBR1', 'SLC6A9', 'CPT2', 'DNAJC7', 'FTH1', 'TXNRD1', 'GSR', 'SLC39A11', 'SLC5A3', 'PRDX6']",0.9163594538883383,0,0,11
21,Amino Acid metabolism WP3925,0.09073053518638237,2.187719005506424,5.2502222141030686,"['RARS', 'ALDH1A1', 'ODC1', 'GSR', 'FAH']",0.9163594538883383,0,0,5
22,Constitutive Androstane Receptor Pathway WP2875,0.09121477204632944,4.364389920424403,10.450699347922162,"['NCOA1', 'DNAJC7']",0.9163594538883383,0,0,2
23,MAPK pathway in congenital thyroid cancer WP4928,0.09121477204632944,4.364389920424403,10.450699347922162,"['ALK', 'GAREM2']",0.9163594538883383,0,0,2
24,Adipogenesis WP236,0.09848837422337377,1.9623688155922039,4.548411341774847,"['NCOA1', 'GDF10', 'IRS1', 'RORA', 'PLIN2', 'LPIN2']",0.9163594538883383,0,0,6
25,EV release from cardiac cells and their functional effects WP3297,0.09902364859982159,14.165591397849463,32.75646513929033,['KLF2'],0.9163594538883383,0,0,1
26,Fatty Acid Omega Oxidation WP206,0.09902364859982159,14.165591397849463,32.75646513929033,['ALDH1A1'],0.9163594538883383,0,0,1
27,Hypothetical Craniofacial Development Pathway WP3655,0.09902364859982159,14.165591397849463,32.75646513929033,['ARHGAP29'],0.9163594538883383,0,0,1
28,MED and Pseudoachondroplasia genes WP4789,0.09902364859982159,14.165591397849463,32.75646513929033,['COL9A2'],0.9163594538883383,0,0,1
29,Triacylglyceride synthesis WP325,0.10197129463387516,4.052339901477833,9.251751063041825,"['AGPAT3', 'PLPP1']",0.9163594538883383,0,0,2
30,Eicosanoid metabolism via cyclooxygenases (COX) WP4719,0.10197129463387516,4.052339901477833,9.251751063041825,"['TBXAS1', 'PTGDS']",0.9163594538883383,0,0,2
31,Pregnane X receptor pathway WP2876,0.10197129463387516,4.052339901477833,9.251751063041825,"['NCOA1', 'DNAJC7']",0.9163594538883383,0,0,2
32,Regulation of Actin Cytoskeleton WP51,0.10934978571094087,1.795030324442089,3.972767381445717,"['CYFIP2', 'PDGFRB', 'ENAH', 'PPP1R12A', 'MRAS', 'IQGAP1', 'ARHGEF6']",0.9163594538883383,0,0,7
33,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.11624447408991956,2.661447084233261,5.72759320090662,"['CTNNA1', 'MAP4K5', 'TEAD1']",0.9163594538883383,0,0,3
34,Hedgehog Signaling Pathway WP4249,0.12377416835025017,2.5806008246612997,5.391640520668925,"['GRK3', 'FBXL17', 'GLI1']",0.9163594538883383,0,0,3
35,Somatic sex determination WP4814,0.12980701512079176,9.443010752688172,19.27985577759018,['PTGDS'],0.9163594538883383,0,0,1
36,Synthesis and Degradation of Ketone Bodies WP311,0.12980701512079176,9.443010752688172,19.27985577759018,['OXCT1'],0.9163594538883383,0,0,1
37,Genes controlling nephrogenesis WP4823,0.13606229886713647,3.3364604462474645,6.655045532822579,"['NOTCH2', 'PDGFRB']",0.9163594538883383,0,0,2
38,Hippo-Merlin Signaling Dysregulation WP4541,0.1380558147248982,1.8945770065075922,3.751446665681925,"['PDGFRB', 'DDB1', 'PPP1R12A', 'CTNNA1', 'TEAD1']",0.9163594538883383,0,0,5
39,Canonical and non-canonical Notch signaling WP3845,0.14792385516423706,3.1508620689655173,6.021478997180267,"['NOTCH2', 'ADAM10']",0.9163594538883383,0,0,2
40,Nucleotide GPCRs WP80,0.1595407994616406,7.081720430107527,12.998183374829578,['ADORA1'],0.9163594538883383,0,0,1
41,Osteoblast Signaling WP322,0.1595407994616406,7.081720430107527,12.998183374829578,['PDGFRB'],0.9163594538883383,0,0,1
42,DNA Repair Pathways Full Network WP4946,0.17426712355206436,1.6394648829431437,2.8644172428867556,"['DDB1', 'RAP1A', 'MSH2', 'FANCC', 'GTF2H3', 'RAD54B']",0.9163594538883383,0,0,6
43,Energy Metabolism WP1541,0.18080535312514964,2.127861771058315,3.639354809853,"['NCOA1', 'PPP3CB', 'NRF1']",0.9163594538883383,0,0,3
44,Exercise-induced Circadian Regulation WP410,0.18080535312514964,2.127861771058315,3.639354809853,"['BTG1', 'CRY2', 'ERC2']",0.9163594538883383,0,0,3
45,One-carbon metabolism and related pathways WP3940,0.18080535312514964,2.127861771058315,3.639354809853,"['CHDH', 'GSR', 'MTR']",0.9163594538883383,0,0,3
46,Oxidative Stress WP408,0.18459471166185093,2.7001231527093594,4.562108111072216,"['TXNRD1', 'GSR']",0.9163594538883383,0,0,2
47,Photodynamic therapy-induced unfolded protein response WP3613,0.18459471166185093,2.7001231527093594,4.562108111072216,"['DNAJB11', 'CALR']",0.9163594538883383,0,0,2
48,Sulfation Biotransformation Reaction WP692,0.1882607116844353,5.66494623655914,9.460049577505979,['GSR'],0.9163594538883383,0,0,1
49,EDA signaling in hair follicle development WP3930,0.1882607116844353,5.66494623655914,9.460049577505979,['GLI1'],0.9163594538883383,0,0,1
50,Genes targeted by miRNAs in adipocytes WP1992,0.1882607116844353,5.66494623655914,9.460049577505979,['PTBP2'],0.9163594538883383,0,0,1
51,Resistin as a regulator of inflammation WP4481,0.2096934927515228,2.4649550224887555,3.8505268791646157,"['PLCE1', 'PLCD1']",0.9163594538883383,0,0,2
52,"Cerebral organic acidurias, including diseases WP4519",0.2160012503332454,4.720430107526882,7.233922637856075,['L2HGDH'],0.9163594538883383,0,0,1
53,Nephrogenesis WP5052,0.2160012503332454,4.720430107526882,7.233922637856075,['NOTCH2'],0.9163594538883383,0,0,1
54,Role of Osx and miRNAs in tooth development WP3971,0.2160012503332454,4.720430107526882,7.233922637856075,['NOTCH2'],0.9163594538883383,0,0,1
55,Copper homeostasis WP3286,0.2160427121019072,1.9338307480856076,2.9631685342120306,"['BACE1', 'ADAM10', 'MAPT']",0.9163594538883383,0,0,3
56,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.2223701685485409,2.3620689655172415,3.551162496487196,"['RAP1A', 'TEAD1']",0.9163594538883383,0,0,2
57,MAPK Signaling Pathway WP382,0.22377495201427308,1.3753794028375803,2.0591003241165904,"['PDGFRB', 'RPS6KA3', 'PPP3CB', 'MRAS', 'RAP1A', 'MAPT', 'HSPA2', 'RASGRP1', 'DUSP16']",0.9163594538883383,0,0,9
58,Rett syndrome causing genes WP4312,0.2250704836630077,1.8907127429805615,2.8196986903596897,"['CDKL5', 'KCNJ10', 'RHOBTB2']",0.9163594538883383,0,0,3
59,Selenium Micronutrient Network WP15,0.23416992048533689,1.8494694337496478,2.6848900743574293,"['TXNRD1', 'GSR', 'MTR']",0.9163594538883383,0,0,3
60,Wnt signaling in kidney disease WP4150,0.23510464203708192,2.267413793103448,3.282590678322668,"['FZD3', 'FZD9']",0.9163594538883383,0,0,2
61,Valproic acid pathway WP3871,0.2427957429113812,4.045775729646698,5.726936149228618,['IVD'],0.9163594538883383,0,0,1
62,Insulin signaling in adipocytes (diabetic condition) WP3635,0.2427957429113812,4.045775729646698,5.726936149228618,['IRS1'],0.9163594538883383,0,0,1
63,Insulin signaling in adipocytes (normal condition) WP3634,0.2427957429113812,4.045775729646698,5.726936149228618,['IRS1'],0.9163594538883383,0,0,1
64,Regulation of sister chromatid separation at the metaphase-anaphase transition WP4240,0.2427957429113812,4.045775729646698,5.726936149228618,['STAG1'],0.9163594538883383,0,0,1
65,Kit receptor signaling pathway WP304,0.2433334367872026,1.8099811589540922,2.558087292646427,"['RPS6KA3', 'INPP5D', 'MAPT']",0.9163594538883383,0,0,3
66,Trans-sulfuration and one-carbon metabolism WP2525,0.247878219708436,2.1800397877984086,3.040758089231211,"['AHCY', 'MTR']",0.9163594538883383,0,0,2
67,p53 transcriptional gene network WP4963,0.2525536128891839,1.7721382289416847,2.43869563710116,"['MSH2', 'SESN1', 'FANCC']",0.9163594538883383,0,0,3
68,"Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.26182320182769137,1.7358399083175386,2.3261744212132562,"['SP3', 'PLCE1', 'PLCD1']",0.9163594538883383,0,0,3
69,Transcriptional cascade regulating adipogenesis WP4211,0.26867638537764155,3.539784946236559,4.652154053948691,['KLF2'],0.9163594538883383,0,0,1
70,Vitamin B12 Disorders WP4271,0.26867638537764155,3.539784946236559,4.652154053948691,['MTR'],0.9163594538883383,0,0,1
71,NLR Proteins WP288,0.26867638537764155,3.539784946236559,4.652154053948691,['EPHB2'],0.9163594538883383,0,0,1
72,Wnt signaling pathway and pluripotency WP399,0.26890013824626857,1.5540532526833897,2.041117166154251,"['FZD3', 'RACGAP1', 'PPP2R2B', 'FZD9']",0.9163594538883383,0,0,4
73,Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.27113513502782594,1.7009935205183586,2.220031160865941,"['SCARB2', 'PLCE1', 'TLN1']",0.9163594538883383,0,0,3
74,Integrin-mediated Cell Adhesion WP185,0.2841849675823466,1.5123809523809524,1.902771784880925,"['VASP', 'RAP1A', 'CAPN2', 'TLN1']",0.9163594538883383,0,0,4
75,Ciliopathies WP4803,0.28483547591491465,1.3333479551402962,1.6744764198936182,"['NME9', 'EFHC1', 'PKD1L1', 'BBIP1', 'CEP41', 'TOPORS', 'GLIS2']",0.9163594538883383,0,0,7
76,15q13.3 copy number variation syndrome WP4942,0.29367428044223115,3.1462365591397847,3.8550333647671122,['MTMR10'],0.9163594538883383,0,0,1
77,TCA cycle in senescence WP5050,0.29367428044223115,3.1462365591397847,3.8550333647671122,['ME2'],0.9163594538883383,0,0,1
78,Development and heterogeneity of the ILC family WP3893,0.29367428044223115,3.1462365591397847,3.8550333647671122,['RORA'],0.9163594538883383,0,0,1
79,Major receptors targeted by epinephrine and norepinephrine WP4589,0.29367428044223115,3.1462365591397847,3.8550333647671122,['ADCY8'],0.9163594538883383,0,0,1
80,Pathways of nucleic acid metabolism and innate immune sensing WP4705,0.29367428044223115,3.1462365591397847,3.8550333647671122,['RNASEH2C'],0.9163594538883383,0,0,1
81,Pathways affected in adenoid cystic carcinoma WP3651,0.2992570835093664,1.6043441053017646,1.9355645779947546,"['NFIB', 'ATRX', 'DTX4']",0.9163594538883383,0,0,3
82,Allograft Rejection WP2328,0.31175941838978605,1.8277252502780867,2.130256700628486,"['COL5A1', 'HLA-E']",0.9163594538883383,0,0,2
83,Disorders of Folate Metabolism and Transport WP4259,0.3178194744630588,2.8313978494623657,3.245551361526629,['MTR'],0.9163594538883383,0,0,1
84,Glutathione metabolism WP100,0.3178194744630588,2.8313978494623657,3.245551361526629,['GSR'],0.9163594538883383,0,0,1
85,Homologous recombination WP186,0.3178194744630588,2.8313978494623657,3.245551361526629,['RAD54B'],0.9163594538883383,0,0,1
86,Leptin Insulin Overlap WP3935,0.3178194744630588,2.8313978494623657,3.245551361526629,['IRS1'],0.9163594538883383,0,0,1
87,Mammalian disorder of sexual development WP4842,0.3178194744630588,2.8313978494623657,3.245551361526629,['PTGDS'],0.9163594538883383,0,0,1
88,Nephrotic syndrome WP4758,0.3370562599584465,1.716692789968652,1.866912711963154,"['SCARB2', 'PLCE1']",0.9163594538883383,0,0,2
89,FOXA2 pathway WP5066,0.3411409932925384,2.573802541544477,2.768020181028312,['IRS1'],0.9163594538883383,0,0,1
90,Folate Metabolism WP176,0.36206664835091396,1.6183497536945812,1.644125165937458,"['AHCY', 'MTR']",0.9163594538883383,0,0,2
91,EGF/EGFR signaling pathway WP437,0.36331341001281214,1.2414154236750239,1.2569199931676784,"['RPS6KA3', 'RAP1A', 'INPP5D', 'PLCE1', 'AP2A1', 'IQGAP1']",0.9163594538883383,0,0,6
92,Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291,0.3636668768952532,2.3591397849462368,2.38631000666534,['UNC13D'],0.9163594538883383,0,0,1
93,Hedgehog Signaling Pathway Netpath WP47,0.3636668768952532,2.3591397849462368,2.38631000666534,['GLI1'],0.9163594538883383,0,0,1
94,Hypertrophy Model WP516,0.3636668768952532,2.3591397849462368,2.38631000666534,['ADAM10'],0.9163594538883383,0,0,1
95,Omega-9 FA synthesis WP4724,0.3636668768952532,2.3591397849462368,2.38631000666534,['ELOVL6'],0.9163594538883383,0,0,1
96,PPAR-alpha pathway WP2878,0.3636668768952532,2.3591397849462368,2.38631000666534,['CPT2'],0.9163594538883383,0,0,1
97,Common Pathways Underlying Drug Addiction WP2636,0.37444035872265025,1.5732758620689655,1.5454646626118704,"['RAP1A', 'ADCY8']",0.9163594538883383,0,0,2
98,Notch Signaling WP268,0.37444035872265025,1.5732758620689655,1.5454646626118704,"['NOTCH2', 'DTX4']",0.9163594538883383,0,0,2
99,"GPCRs, Class A Rhodopsin-like WP455",0.37452857347951946,1.3930885529157668,1.3681344101782877,"['GPR35', 'GPER1', 'ADORA1']",0.9163594538883383,0,0,3
100,Focal Adhesion WP306,0.3755656494522058,1.2233656553018455,1.1980688892258085,"['VASP', 'PDGFRB', 'RAP1A', 'PPP1R12A', 'CAPN2', 'TLN1']",0.9163594538883383,0,0,6
101,Thermogenesis WP4321,0.3853105143645776,1.2876820149547423,1.228069727603071,"['RPS6KA3', 'CPT2', 'ADCY8', 'CREB5']",0.9163594538883383,0,0,4
102,Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway WP3670,0.3854242125879624,2.1775020678246486,2.0760537716260146,['NRF1'],0.9163594538883383,0,0,1
103,Type II diabetes mellitus WP1584,0.3854242125879624,2.1775020678246486,2.0760537716260146,['IRS1'],0.9163594538883383,0,0,1
104,Cori Cycle WP1946,0.3854242125879624,2.1775020678246486,2.0760537716260146,['PFKP'],0.9163594538883383,0,0,1
105,Imatinib and Chronic Myeloid Leukemia WP3640,0.3854242125879624,2.1775020678246486,2.0760537716260146,['PDGFRB'],0.9163594538883383,0,0,1
106,Phytochemical activity on NRF2 transcriptional activation WP3,0.3854242125879624,2.1775020678246486,2.0760537716260146,['EPHB2'],0.9163594538883383,0,0,1
107,Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds WP3664,0.3854242125879624,2.1775020678246486,2.0760537716260146,['DKK3'],0.9163594538883383,0,0,1
108,Glycogen Synthesis and Degradation WP500,0.38671504951986607,1.5306383970177073,1.4542092799065722,"['PYGB', 'PPP2R2B']",0.9163594538883383,0,0,2
109,Netrin-UNC5B signaling pathway WP4747,0.38671504951986607,1.5306383970177073,1.4542092799065722,"['INPP5D', 'RLF']",0.9163594538883383,0,0,2
110,Regulation of Microtubule Cytoskeleton WP2038,0.38671504951986607,1.5306383970177073,1.4542092799065722,"['MAPT', 'EPHB2']",0.9163594538883383,0,0,2
111,VEGFA-VEGFR2 Signaling Pathway WP3888,0.3898572891206226,1.1121811556481,1.0476463237656655,"['LARP7', 'ADAM10', 'PDE4DIP', 'AP2A1', 'IQGAP1', 'PRDX6', 'MOV10', 'RAP1A', 'CSRP1', 'CTNNA1', 'CAPN2', 'TPP1', 'CALR', 'EPHB2']",0.9163594538883383,0,0,14
112,16p11.2 proximal deletion syndrome WP4949,0.39317235460234035,1.3486578216599814,1.2589817894502913,"['PPP4R1', 'PPP4R2', 'PPP4R4']",0.9163594538883383,0,0,3
113,LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.39317235460234035,1.3486578216599814,1.2589817894502913,"['FZD3', 'H2AFY2', 'FZD9']",0.9163594538883383,0,0,3
114,Ciliary landscape WP4352,0.39641290532235357,1.1567596470902772,1.0703484530123246,"['WDR26', 'MSH2', 'CDH23', 'MCM5', 'ARMC8', 'IQGAP1', 'BBIP1', 'SNAP29']",0.9163594538883383,0,0,8
115,TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc) WP2453,0.40643916754000825,2.0218125960061446,1.820280359560625,['ACO1'],0.9163594538883383,0,0,1
116,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.40643916754000825,2.0218125960061446,1.820280359560625,['LPP'],0.9163594538883383,0,0,1
117,Mitochondrial complex III assembly WP4921,0.40643916754000825,2.0218125960061446,1.820280359560625,['UQCR10'],0.9163594538883383,0,0,1
118,ATM Signaling Network in Development and Disease  WP3878,0.4109373229514066,1.4519230769230769,1.2912163541108281,"['PPM1D', 'HMGN1']",0.9163594538883383,0,0,2
119,Eukaryotic Transcription Initiation WP405,0.4228714395912579,1.4155172413793105,1.2183173890650607,"['POLR1A', 'GTF2H3']",0.9163594538883383,0,0,2
120,Serotonin Receptor 4/6/7 and NR3C Signaling WP734,0.42673701977407813,1.8868817204301076,1.6068445743158746,['RAP1A'],0.9163594538883383,0,0,1
121,Transcription co-factors SKI and SKIL protein partners WP4533,0.42673701977407813,1.8868817204301076,1.6068445743158746,['TEAD1'],0.9163594538883383,0,0,1
122,miRNA targets in ECM and membrane receptors WP2911,0.42673701977407813,1.8868817204301076,1.6068445743158746,['COL5A1'],0.9163594538883383,0,0,1
123,nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell WP5027,0.42673701977407813,1.8868817204301076,1.6068445743158746,['EIF3E'],0.9163594538883383,0,0,1
124,Integrated breast cancer pathway WP1984,0.4450604059017094,1.1509973017300672,0.9317844126839984,"['RAP1A', 'MSH2', 'RASGEF1A', 'IRS1', 'ODC1']",0.9163594538883383,0,0,5
125,Transcription factor regulation in adipogenesis WP3599,0.4463421884610553,1.7688172043010753,1.4268506818380347,['IRS1'],0.9163594538883383,0,0,1
126,Urea cycle and metabolism of amino groups WP497,0.4463421884610553,1.7688172043010753,1.4268506818380347,['ODC1'],0.9163594538883383,0,0,1
127,Mitochondrial LC-Fatty Acid Beta-Oxidation WP368,0.4463421884610553,1.7688172043010753,1.4268506818380347,['CPT2'],0.9163594538883383,0,0,1
128,Synaptic Vesicle Pathway WP2267,0.4463562932679493,1.3479064039408868,1.0872722320918806,"['RIMS1', 'AP2A1']",0.9163594538883383,0,0,2
129,Nucleotide Excision Repair WP4753,0.4463562932679493,1.3479064039408868,1.0872722320918806,"['DDB1', 'GTF2H3']",0.9163594538883383,0,0,2
130,Genotoxicity pathway WP4286,0.4578968934678518,1.316459502806736,1.0283013194452186,"['PPM1D', 'TOPORS']",0.9163594538883383,0,0,2
131,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.4584387348707149,1.132407809110629,0.8831972564365723,"['RPS6KA3', 'CDKL5', 'RAP1A', 'IRS1', 'MAPT']",0.9163594538883383,0,0,5
132,Serotonin Receptor 2 and ELK-SRF/GATA4 signaling WP732,0.4652782628810708,1.6646426312460467,1.2736507667117276,['RASGRP1'],0.9163594538883383,0,0,1
133,Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex WP3657,0.4652782628810708,1.6646426312460467,1.2736507667117276,['ZFX'],0.9163594538883383,0,0,1
134,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,0.4652782628810708,1.6646426312460467,1.2736507667117276,['MRAS'],0.9163594538883383,0,0,1
135,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612,0.4652782628810708,1.6646426312460467,1.2736507667117276,['NQO2'],0.9163594538883383,0,0,1
136,Purinergic signaling WP4900,0.4652782628810708,1.6646426312460467,1.2736507667117276,['ADORA1'],0.9163594538883383,0,0,1
137,Pathways in clear cell renal cell carcinoma WP4018,0.4659770632203983,1.1959662945274236,0.9132624263486698,"['PDGFRB', 'SDSL', 'PFKP']",0.9163594538883383,0,0,3
138,IL-4 signaling pathway WP395,0.469297004360225,1.2864420062695925,0.9732183854174395,"['IRS1', 'INPP5D']",0.9163594538883383,0,0,2
139,Interferon type I signaling pathways WP585,0.48055274574371704,1.2577586206896552,0.9217085140707755,"['RAP1A', 'IRS1']",0.9163594538883383,0,0,2
140,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.48055274574371704,1.2577586206896552,0.9217085140707755,"['DDX17', 'DHX58']",0.9163594538883383,0,0,2
141,T-Cell Receptor and Co-stimulatory Signaling WP2583,0.4835680308190383,1.5720430107526882,1.1421887090378822,['RASGRP1'],0.9163594538883383,0,0,1
142,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.4835680308190383,1.5720430107526882,1.1421887090378822,['H2AFY2'],0.9163594538883383,0,0,1
143,Hippo-Yap signaling pathway WP4537,0.4835680308190383,1.5720430107526882,1.1421887090378822,['TEAD1'],0.9163594538883383,0,0,1
144,Mitochondrial Gene Expression WP391,0.4835680308190383,1.5720430107526882,1.1421887090378822,['NRF1'],0.9163594538883383,0,0,1
145,Signal Transduction of S1P Receptor WP26,0.5012335053792595,1.4891907187323146,1.0285590227544674,['RACGAP1'],0.9163594538883383,0,0,1
146,Hair Follicle Development: Organogenesis - Part 2 of 3 WP2839,0.5012335053792595,1.4891907187323146,1.0285590227544674,['GLI1'],0.9163594538883383,0,0,1
147,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.5066480944538605,1.0882450882450883,0.7399398528201777,"['NOTCH2', 'FZD3', 'PDCD6', 'FZD9']",0.9163594538883383,0,0,4
148,Androgen receptor signaling pathway WP138,0.5094834677801284,1.1168580197794702,0.7531620006437794,"['NCOA1', 'CALR', 'PLPP1']",0.9163594538883383,0,0,3
149,Sphingolipid Metabolism (general overview) WP4725,0.5182959516305419,1.4146236559139784,0.9297032068503915,['DEGS2'],0.9163594538883383,0,0,1
150,Differentiation Pathway WP2848,0.5182959516305419,1.4146236559139784,0.9297032068503915,['ALK'],0.9163594538883383,0,0,1
151,EPO Receptor Signaling WP581,0.5182959516305419,1.4146236559139784,0.9297032068503915,['IRS1'],0.9163594538883383,0,0,1
152,Osteoblast differentiation WP4787,0.5263604136024345,1.0880544941020103,0.6982797576980281,"['NOTCH2', 'FZD3', 'FZD9']",0.9163594538883383,0,0,3
153,Notch Signaling Pathway Netpath WP61,0.5345586912959106,1.131551724137931,0.7087064020411701,"['NOTCH2', 'MAPT']",0.9163594538883383,0,0,2
154,Sphingolipid Metabolism (integrated pathway) WP4726,0.5347759117609447,1.34715821812596,0.8431964005549181,['DEGS2'],0.9163594538883383,0,0,1
155,TLR4 Signaling and Tolerance WP3851,0.5347759117609447,1.34715821812596,0.8431964005549181,['INPP5D'],0.9163594538883383,0,0,1
156,DNA Mismatch Repair WP531,0.5347759117609447,1.34715821812596,0.8431964005549181,['MSH2'],0.9163594538883383,0,0,1
157,Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome WP4320,0.5347759117609447,1.34715821812596,0.8431964005549181,['MTA2'],0.9163594538883383,0,0,1
158,Estrogen signaling pathway WP712,0.5347759117609447,1.34715821812596,0.8431964005549181,['GPER1'],0.9163594538883383,0,0,1
159,Fluoropyrimidine Activity WP1601,0.5347759117609447,1.34715821812596,0.8431964005549181,['UPP2'],0.9163594538883383,0,0,1
160,NRF2-ARE regulation WP4357,0.5347759117609447,1.34715821812596,0.8431964005549181,['EPHB2'],0.9163594538883383,0,0,1
161,Ras signaling WP4223,0.5363686678680799,1.0322687904745318,0.6430348530789399,"['PDGFRB', 'RAP1A', 'MRAS', 'PLCE1', 'RASGRP1']",0.9163594538883383,0,0,5
162,Circadian rhythm related genes WP3594,0.5426387826644138,1.024709987739319,0.626416903044326,"['AHCY', 'CRY2', 'ADORA1', 'RORA', 'PTGDS']",0.9163594538883383,0,0,5
163,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.5494345959679595,1.0284140102321921,0.6158817083402732,"['RPS6KA3', 'IRS1', 'MAP4K5', 'RHOQ']",0.9163594538883383,0,0,4
164,Breast cancer pathway WP4262,0.5494345959679595,1.0284140102321921,0.6158817083402732,"['NOTCH2', 'NCOA1', 'FZD3', 'FZD9']",0.9163594538883383,0,0,4
165,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.5506932295595334,1.2858260019550343,0.7670947035682092,['TMEM38B'],0.9163594538883383,0,0,1
166,Physiological and pathological hypertrophy of the heart WP1528,0.5506932295595334,1.2858260019550343,0.7670947035682092,['PPP3CB'],0.9163594538883383,0,0,1
167,Pre-implantation embryo WP3527,0.5506932295595334,1.2858260019550343,0.7670947035682092,['H2AFY2'],0.9163594538883383,0,0,1
168,Male infertility WP4673,0.5510613528925703,1.0475161987041037,0.6242244642901016,"['MTR', 'MLH3', 'PUM2']",0.9163594538883383,0,0,3
169,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.555058495250825,1.0878647214854111,0.6404061340521106,"['FZD3', 'FZD9']",0.9163594538883383,0,0,2
170,3q29 copy number variation syndrome WP4906,0.5650660291854646,1.0672576447625244,0.6092042059015388,"['ADAM10', 'PIGM']",0.9163594538883383,0,0,2
171,MET in type 1 papillary renal cell carcinoma WP4205,0.5650660291854646,1.0672576447625244,0.6092042059015388,"['ALK', 'RAP1A']",0.9163594538883383,0,0,2
172,Sphingolipid pathway WP1422,0.5660670742948688,1.2298270219728846,0.6998240915501036,['PLPP1'],0.9163594538883383,0,0,1
173,Aryl Hydrocarbon Receptor Pathway WP2873,0.5660670742948688,1.2298270219728846,0.6998240915501036,['NCOA1'],0.9163594538883383,0,0,1
174,Tryptophan metabolism WP465,0.5660670742948688,1.2298270219728846,0.6998240915501036,['ALDH1A1'],0.9163594538883383,0,0,1
175,TYROBP causal network in microglia WP3945,0.5660670742948688,1.2298270219728846,0.6998240915501036,['ADAP2'],0.9163594538883383,0,0,1
176,Glycerophospholipid Biosynthetic Pathway WP2533,0.5660670742948688,1.2298270219728846,0.6998240915501036,['LPIN2'],0.9163594538883383,0,0,1
177,MTHFR deficiency WP4288,0.5660670742948688,1.2298270219728846,0.6998240915501036,['CHDH'],0.9163594538883383,0,0,1
178,Wnt signaling WP428,0.5670997798744422,1.0221187124307163,0.5797661884553484,"['FZD3', 'PPP3CB', 'FZD9']",0.9163594538883383,0,0,3
179,ESC Pluripotency Pathways WP3931,0.5670997798744422,1.0221187124307163,0.5797661884553484,"['PDGFRB', 'FZD3', 'FZD9']",0.9163594538883383,0,0,3
180,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.5800681341355088,0.974607467508076,0.5307806899448018,"['PDGFRB', 'COL5A1', 'CAB39L', 'IRS1', 'PPP2R2B', 'COL11A1', 'CREB5']",0.9163594538883383,0,0,7
181,Vitamin B12 metabolism WP1533,0.5809159635172502,1.178494623655914,0.6400983810462939,['MTR'],0.9163594538883383,0,0,1
182,7q11.23 copy number variation syndrome WP4932,0.5904873652742615,0.9862373800793611,0.5195567951640535,"['FZD9', 'HSPA2', 'DEK']",0.9163594538883383,0,0,3
183,ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,0.5941099543278273,1.0098522167487685,0.5258208277490256,"['FZD3', 'FZD9']",0.9163594538883383,0,0,2
184,Vitamin A and carotenoid metabolism WP716,0.5952577850915304,1.131268817204301,0.5868578204797155,['ALDH1A1'],0.9163594538883383,0,0,1
185,GABA receptor Signaling WP4159,0.5952577850915304,1.131268817204301,0.5868578204797155,['AP2A1'],0.9163594538883383,0,0,1
186,Nanoparticle-mediated activation of receptor signaling WP2643,0.5952577850915304,1.131268817204301,0.5868578204797155,['TLN1'],0.9163594538883383,0,0,1
187,Renin-angiotensin-aldosterone system (RAAS) WP4756,0.5952577850915304,1.131268817204301,0.5868578204797155,['CREB5'],0.9163594538883383,0,0,1
188,Proteasome Degradation WP183,0.6034638537522589,0.992059891107078,0.5010588306735604,"['PSME2', 'HLA-E']",0.9163594538883383,0,0,2
189,Melatonin metabolism and effects WP3298,0.6091098186541688,1.0876757650951199,0.5392225494220254,['CRY2'],0.9163594538883383,0,0,1
190,MECP2 and Associated Rett Syndrome WP3584,0.6126539854405626,0.9748810939357907,0.47764783065891425,"['CSRP1', 'SP3']",0.9163594538883383,0,0,2
191,Cell cycle WP179,0.6130462733419987,0.9527750139539398,0.4662069718052223,"['STAG1', 'CDC27', 'MCM5']",0.9163594538883383,0,0,3
192,Nuclear receptors WP170,0.6224887561273231,1.0473118279569893,0.49645692549237136,['RORA'],0.9163594538883383,0,0,1
193,Head and Neck Squamous Cell Carcinoma WP4674,0.630544118699931,0.9422413793103448,0.4345354844849021,"['NOTCH2', 'SESN1']",0.9163594538883383,0,0,2
194,Alpha 6 Beta 4 signaling pathway WP244,0.6354107218237682,1.0098310291858679,0.45794189448105055,['IRS1'],0.9163594538883383,0,0,1
195,Zinc homeostasis WP3529,0.6354107218237682,1.0098310291858679,0.45794189448105055,['SLC39A11'],0.9163594538883383,0,0,1
196,Development of ureteric collection system WP5053,0.6354107218237682,1.0098310291858679,0.45794189448105055,['GLI1'],0.9163594538883383,0,0,1
197,Neovascularisation processes WP4331,0.6354107218237682,1.0098310291858679,0.45794189448105055,['EPHB2'],0.9163594538883383,0,0,1
198,PDGFR-beta pathway WP3972,0.6354107218237682,1.0098310291858679,0.45794189448105055,['PDGFRB'],0.9163594538883383,0,0,1
199,Neural Crest Differentiation WP2064,0.6477843653627342,0.9117074527252503,0.39586101238255694,"['NOTCH2', 'FZD3']",0.9163594538883383,0,0,2
200,ATM Signaling Pathway WP2516,0.6478912917784935,0.974935113088617,0.4231533843775235,['AP3B2'],0.9163594538883383,0,0,1
201,Fatty acid beta-oxidation WP143,0.6478912917784935,0.974935113088617,0.4231533843775235,['CPT2'],0.9163594538883383,0,0,1
202,miRNA regulation of prostate cancer signaling pathways WP3981,0.6478912917784935,0.974935113088617,0.4231533843775235,['PDGFRB'],0.9163594538883383,0,0,1
203,Neural Crest Cell Migration during Development WP4564,0.6478912917784935,0.974935113088617,0.4231533843775235,['EPHB2'],0.9163594538883383,0,0,1
204,Tumor suppressor activity of SMARCB1 WP4204,0.6599455120033683,0.9423655913978495,0.39164525970941116,['GLI1'],0.9163594538883383,0,0,1
205,Type 2 papillary renal cell carcinoma WP4241,0.6599455120033683,0.9423655913978495,0.39164525970941116,['COL21A1'],0.9163594538883383,0,0,1
206,Vitamin D-sensitive calcium signaling in depression WP4698,0.6599455120033683,0.9423655913978495,0.39164525970941116,['GSR'],0.9163594538883383,0,0,1
207,Initiation of transcription and translation elongation at the HIV-1 LTR WP3414,0.6599455120033683,0.9423655913978495,0.39164525970941116,['PPP3CB'],0.9163594538883383,0,0,1
208,DNA IR-damage and cellular response via ATR WP4016,0.6643811431980796,0.8830818965517241,0.36109155463620457,"['MSH2', 'PPM1D']",0.9163594538883383,0,0,2
209,Signaling of Hepatocyte Growth Factor Receptor WP313,0.6715879167267697,0.9118973291710024,0.36303576096952195,['RAP1A'],0.9163594538883383,0,0,1
210,Amyotrophic lateral sclerosis (ALS) WP2447,0.6715879167267697,0.9118973291710024,0.36303576096952195,['PPP3CB'],0.9163594538883383,0,0,1
211,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling WP3850,0.6715879167267697,0.9118973291710024,0.36303576096952195,['IRS1'],0.9163594538883383,0,0,1
212,IL-5 signaling pathway WP127,0.6715879167267697,0.9118973291710024,0.36303576096952195,['MAPT'],0.9163594538883383,0,0,1
213,mBDNF and proBDNF regulation of GABA neurotransmission WP4829,0.6715879167267697,0.9118973291710024,0.36303576096952195,['AP2A1'],0.9163594538883383,0,0,1
214,p38 MAPK Signaling Pathway WP400,0.6715879167267697,0.9118973291710024,0.36303576096952195,['HMGN1'],0.9163594538883383,0,0,1
215,Leptin signaling pathway WP2034,0.6724408103795946,0.8694297082228116,0.3450255162809604,"['NCOA1', 'IRS1']",0.9163594538883383,0,0,2
216,Disruption of postsynaptic signaling by CNV WP4875,0.682832545918536,0.8833333333333333,0.33699663437618615,['DLGAP1'],0.9163594538883383,0,0,1
217,Glycolysis and Gluconeogenesis WP534,0.682832545918536,0.8833333333333333,0.33699663437618615,['PFKP'],0.9163594538883383,0,0,1
218,Neural Crest Cell Migration in Cancer WP4565,0.682832545918536,0.8833333333333333,0.33699663437618615,['EPHB2'],0.9163594538883383,0,0,1
219,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.6880888539485229,0.8433479155944416,0.31527490874412956,"['ADCY8', 'MAP4K5']",0.9163594538883383,0,0,2
220,Target Of Rapamycin (TOR) Signaling WP1471,0.6936929617338211,0.8565004887585532,0.3132443561054929,['RRAGD'],0.9163594538883383,0,0,1
221,DNA Replication WP466,0.6936929617338211,0.8565004887585532,0.3132443561054929,['MCM5'],0.9163594538883383,0,0,1
222,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.6936929617338211,0.8565004887585532,0.3132443561054929,['RPS6KA3'],0.9163594538883383,0,0,1
223,IL-2 signaling pathway WP49,0.6936929617338211,0.8565004887585532,0.3132443561054929,['MAPT'],0.9163594538883383,0,0,1
224,Mesodermal commitment pathway WP2857,0.6947023803947286,0.8388041827940893,0.3055526715846477,"['SESN1', 'TEAD1', 'PARP8']",0.9163594538883383,0,0,3
225,Glioblastoma signaling pathways WP2261,0.6956799896697724,0.8308823529411765,0.30149854820033434,"['PDGFRB', 'IRS1']",0.9163594538883383,0,0,2
226,Fas ligand pathway and stress induction of heat shock proteins WP314,0.7041822649007701,0.8312460468058191,0.29153299869555727,['DFFA'],0.9163594538883383,0,0,1
227,Ferroptosis WP4313,0.7041822649007701,0.8312460468058191,0.29153299869555727,['FTH1'],0.9163594538883383,0,0,1
228,G13 Signaling Pathway WP524,0.7041822649007701,0.8312460468058191,0.29153299869555727,['IQGAP1'],0.9163594538883383,0,0,1
229,Integrated Cancer Pathway WP1971,0.7041822649007701,0.8312460468058191,0.29153299869555727,['MSH2'],0.9163594538883383,0,0,1
230,IL-6 signaling pathway WP364,0.714313110375249,0.8074347158218126,0.2716483965767846,['NCOA1'],0.9214948350295421,0,0,1
231,PDGF Pathway WP2526,0.714313110375249,0.8074347158218126,0.2716483965767846,['PDGFRB'],0.9214948350295421,0,0,1
232,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.71754019432969,0.7955925206410879,0.26407809198359394,"['PDGFRB', 'MRAS']",0.921668008233826,0,0,2
233,Pathways Regulating Hippo Signaling WP4540,0.7245280509505969,0.7844827586206896,0.25278764506507173,"['PDGFRB', 'TEAD1']",0.9223513801771388,0,0,2
234,Insulin Signaling WP481,0.7246784184466761,0.8120464667227257,0.2615011175862708,"['RPS6KA3', 'IRS1', 'MAP4K5', 'RHOQ']",0.9223513801771388,0,0,4
235,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.7303569287596943,0.7914050988070487,0.24867683029958848,"['DEAF1', 'SP3', 'RORA']",0.9223513801771388,0,0,3
236,IL-3 signaling pathway WP286,0.7335479097381943,0.763673350770125,0.23663363202003598,['INPP5D'],0.9223513801771388,0,0,1
237,SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.7335479097381943,0.763673350770125,0.23663363202003598,['DHX58'],0.9223513801771388,0,0,1
238,Complement system WP2806,0.7426750783136448,0.7435200905489531,0.22119472900235,['CALR'],0.929904089653219,0,0,1
239,Endochondral Ossification with Skeletal Dysplasias WP4808,0.7514902465580047,0.7244003308519438,0.20695903646073124,['SLC38A2'],0.9331003894761891,0,0,1
240,Endochondral Ossification WP474,0.7514902465580047,0.7244003308519438,0.20695903646073124,['SLC38A2'],0.9331003894761891,0,0,1
241,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) WP4718,0.7600040575672382,0.7062365591397849,0.19381356309027772,['TM7SF2'],0.9358727651034585,0,0,1
242,Histone Modifications WP2369,0.7600040575672382,0.7062365591397849,0.19381356309027772,['SETBP1'],0.9358727651034585,0,0,1
243,Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.768226792246935,0.6889588250721217,0.18165797115364005,['ADCY8'],0.9358975298612446,0,0,1
244,Phosphodiesterases in neuronal function WP4222,0.768226792246935,0.6889588250721217,0.18165797115364005,['ADCY8'],0.9358975298612446,0,0,1
245,22q11.2 copy number variation syndrome WP4657,0.7694459557584059,0.7145896988214754,0.1872829275837775,"['SNAP29', 'DGCR2']",0.9358975298612446,0,0,2
246,Endoplasmic reticulum stress response in coronavirus infection WP4861,0.7761683813460295,0.6725038402457757,0.17040292091837195,['PPP1R12A'],0.9402364944760846,0,0,1
247,Regulation of toll-like receptor signaling pathway WP1449,0.7810534938036413,0.6968390804597702,0.1721970462473282,"['RNF31', 'SFTPD']",0.9423236483946766,0,0,2
248,Hepatitis B infection WP4666,0.7871241646310578,0.7170260277482886,0.171633999317695,"['DDB1', 'HSPG2', 'CREB5']",0.945818552661513,0,0,3
249,PPAR signaling pathway WP3942,0.7912461672816856,0.6418377321603128,0.1502838335334953,['CPT2'],0.9469532443772783,0,0,1
250,Electron Transport Chain (OXPHOS system in mitochondria) WP111,0.7975041317206818,0.6717980295566502,0.15200657356753397,"['UQCR10', 'ATP5ME']",0.9479018848488978,0,0,2
251,G1 to S cell cycle control WP45,0.7984005808626622,0.6275268817204301,0.14128443087875595,['MCM5'],0.9479018848488978,0,0,1
252,mRNA Processing WP411,0.8051600487530378,0.693304535637149,0.15024893987589347,"['SNRPD1', 'SREK1', 'PTBP2']",0.948190677244841,0,0,3
253,Metapathway biotransformation Phase I and II WP702,0.8177327880884001,0.6410658307210031,0.12899504892776487,"['GSR', 'NAT10']",0.948190677244841,0,0,2
254,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.8184288002988359,0.5881720430107527,0.11785136996630168,['CTNNA1'],0.948190677244841,0,0,1
255,Translation Factors WP107,0.8184288002988359,0.5881720430107527,0.11785136996630168,['EIF3E'],0.948190677244841,0,0,1
256,DNA damage response WP707,0.8246534324045837,0.5761246434057494,0.11107225845540034,['SESN1'],0.948190677244841,0,0,1
257,Mitochondrial complex I assembly model OXPHOS system WP4324,0.8246534324045837,0.5761246434057494,0.11107225845540034,['NDUFAF2'],0.948190677244841,0,0,1
258,Oxidative phosphorylation WP623,0.8246534324045837,0.5761246434057494,0.11107225845540034,['ATP5ME'],0.948190677244841,0,0,1
259,Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.8364711069023739,0.5534471853257432,0.09882535557450114,['CTNNA1'],0.948190677244841,0,0,1
260,IL-1 signaling pathway WP195,0.8364711069023739,0.5534471853257432,0.09882535557450114,['HSPB2'],0.948190677244841,0,0,1
261,miRNA regulation of DNA damage response WP1530,0.8364711069023739,0.5534471853257432,0.09882535557450114,['SESN1'],0.948190677244841,0,0,1
262,Acute viral myocarditis WP4298,0.842078442200152,0.5427626137303556,0.09329118182313444,['DFFA'],0.948190677244841,0,0,1
263,AGE/RAGE pathway WP2324,0.842078442200152,0.5427626137303556,0.09329118182313444,['IRS1'],0.948190677244841,0,0,1
264,RAC1/PAK1/p38/MMP2 Pathway WP3303,0.8474939004371235,0.5324812335159261,0.08811054131657399,['MSH2'],0.948190677244841,0,0,1
265,Regulatory circuits of the STAT3 signaling pathway WP4538,0.8474939004371235,0.5324812335159261,0.08811054131657399,['PDGFRB'],0.948190677244841,0,0,1
266,Ebola Virus Pathway on Host WP4217,0.8488176017264001,0.5935117967332123,0.09728308523296102,"['IQGAP1', 'HLA-E']",0.948190677244841,0,0,2
267,Endoderm differentiation WP2853,0.85677026608773,0.5811855670103093,0.08984284048622151,"['SESN1', 'PARP8']",0.948190677244841,0,0,2
268,Oncostatin M Signaling Pathway WP2374,0.8577751708965957,0.5130400782013685,0.07870714701577879,['IRS1'],0.948190677244841,0,0,1
269,PI3K-Akt signaling pathway WP4172,0.860059895213302,0.6729182451296848,0.10144461012468436,"['PDGFRB', 'IRS1', 'PPP2R2B', 'COL9A2', 'CREB5']",0.948190677244841,0,0,5
270,AMP-activated protein kinase (AMPK) signaling WP1403,0.8626534253178975,0.5038402457757296,0.07443849733032201,['SLC2A4RG'],0.948190677244841,0,0,1
271,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.8673647017546108,0.4949632144878325,0.0704311582245947,['HSPA2'],0.948190677244841,0,0,1
272,Apoptosis WP254,0.8719147038964775,0.4863922877271042,0.06666671517225692,['DFFA'],0.948190677244841,0,0,1
273,Thyroid stimulating hormone (TSH) signaling pathway WP2032,0.8719147038964775,0.4863922877271042,0.06666671517225692,['RAP1A'],0.948190677244841,0,0,1
274,Endometrial cancer WP4155,0.8719147038964775,0.4863922877271042,0.06666671517225692,['CTNNA1'],0.948190677244841,0,0,1
275,Chemokine signaling pathway WP3929,0.8750081753098364,0.5524847870182555,0.07376890105645212,"['RAP1A', 'ADCY8']",0.948190677244841,0,0,2
276,Prolactin Signaling Pathway WP2037,0.8886093738514859,0.45487339576829694,0.05371942883544415,['IRS1'],0.9508638491775232,0,0,1
277,Chromosomal and microsatellite instability in colorectal cancer  WP4216,0.8924319805756341,0.44761904761904764,0.05094127697355209,['MSH2'],0.9508638491775232,0,0,1
278,Non-small cell lung cancer WP4255,0.8961236756388739,0.4405913978494624,0.0483226743117601,['ALK'],0.9508638491775232,0,0,1
279,Retinoblastoma gene in cancer WP2446,0.8996889330229478,0.4337799834574028,0.04585323601940463,['HMGB2'],0.9508638491775232,0,0,1
280,Apoptosis Modulation and Signaling WP1772,0.9031320740016224,0.42717497556207235,0.04352335242869637,['DFFA'],0.9508638491775232,0,0,1
281,Calcium Regulation in the Cardiac Cell WP536,0.9078433323287224,0.4982834909978639,0.04817577035413562,"['CALR', 'ADCY8']",0.9508638491775232,0,0,2
282,Fragile X Syndrome  WP4549,0.9103903841815887,0.4938747731397459,0.04636584174085904,"['CYFIP2', 'AP2A1']",0.9508638491775232,0,0,2
283,Corticotropin-releasing hormone signaling pathway WP2355,0.912769831995489,0.4085086489013558,0.03728520978809247,['GRK3'],0.9508638491775232,0,0,1
284,MicroRNAs in cardiomyocyte hypertrophy WP1544,0.912769831995489,0.4085086489013558,0.03728520978809247,['PPP3CB'],0.9508638491775232,0,0,1
285,Myometrial relaxation and contraction pathways WP289,0.912871449416507,0.48954272863568216,0.04462681721278556,"['ADCY8', 'PLCD1']",0.9508638491775232,0,0,2
286,B Cell Receptor Signaling Pathway WP23,0.9157648480333865,0.40264208909370197,0.03543075773692028,['INPP5D'],0.9508638491775232,0,0,1
287,Joubert Syndrome WP4656,0.9157648480333865,0.40264208909370197,0.03543075773692028,['CEP41'],0.9508638491775232,0,0,1
288,Pyrimidine metabolism WP4022,0.9241480777472427,0.38600677566651936,0.03044935815558625,['POLR1A'],0.9555500010979073,0,0,1
289,Spinal Cord Injury WP2431,0.9267531831000684,0.3807614065678582,0.02896375953760738,['VCAN'],0.9555500010979073,0,0,1
290,Vitamin D Receptor Pathway WP2877,0.9316985816546481,0.3706847764572722,0.02622443807843534,['RASGRP1'],0.9555500010979073,0,0,1
291,Pancreatic adenocarcinoma pathway WP4263,0.9340448784661946,0.36584275939114647,0.0249617412785169,['ARHGEF6'],0.9555500010979073,0,0,1
292,G Protein Signaling Pathways WP35,0.9363107393308353,0.36112489660876756,0.023764860659774737,['ADCY8'],0.9555500010979073,0,0,1
293,Nonalcoholic fatty liver disease WP4396,0.9397774064996276,0.43938577586206895,0.027291231843719295,"['IRS1', 'UQCR10']",0.9558145636071298,0,0,2
294,Cytoplasmic Ribosomal Proteins WP477,0.95013926349243,0.3312080961416825,0.016940205099249917,['RPS6KA3'],0.9597744243863334,0,0,1
295,DNA damage response (only ATM dependent) WP710,0.95013926349243,0.3312080961416825,0.016940205099249917,['IRS1'],0.9597744243863334,0,0,1
296,IL-18 signaling pathway WP4754,0.9533329852964922,0.46519814326456094,0.022232297913646417,"['PYGB', 'DEK', 'KLF2']",0.9597744243863334,0,0,3
297,Gastrin signaling pathway WP4659,0.9609701761547174,0.3058438522674147,0.012176226290880027,['IRS1'],0.9642057659734202,0,0,1
298,Ectoderm Differentiation WP2858,0.9831609348596894,0.2421208750463478,0.004111806663708144,['HMGB2'],0.9831609348596894,0,0,1
